Main content

    Kidney and Pancreas Transplant Program

    Kidney and Pancreas Transplant ProgramOpens new window | Adult Clinical Trials Main Page

    Further protocol information can be found on the links below at ClinicalTrials.gov


    Active Trials

    Title: Natural History of Infection Caused by BK Virus (and Other Opportunistic Viral Pathogens) in Renal Transplant Recipients
    Description: The purpose of this study is to characterize the natural history of BK viremia
    Investigator: V. Ram Peddi, MD
    Eligibility: Subjects, 18 years and older, who received a renal or renal-pancreas transplant at risk for BK virus infection
    Status: Active and open to enrollment
    Contact: Alejandra Alvarez, 415-600-1627, Email: AlvarA9@cpmcri.org about Study BK Natural History

    Title: Evaluation of the Benefits and Risks in Maintenance Renal Transplant Recipients Following Conversion to Nulojix® (Belatacept)-Based Immunosuppression
    Description: The primary purpose is to assess the benefits and risks of changing from Cyclosporine or Tacrolimus to Belatacept between 6-36 months after kidney transplant
    Investigator: V. Ram Peddi, MD
    Eligibility: Subject between 18 and 75 years old who are recipients of a renal allograft from a living donor or a deceased donor between 6-36 months prior to enrollment
    Status: Active and open to enrollment
    Contact: Serena Lai, 415-600-1744, Email: LaiS@cpmcri.org about Study BMS 116

    Title: Evaluation of Acute Rejection Rates in de Novo Renal Transplant Recipients Following Thymoglobulin Induction, CNI-free, Nulojix (Belatacept)-Based Immunosuppression
    Description: A 2 year study evaluating the efficacy of the combination of Thymoglobulin induction, belatacept, everolimus and corticosteroid withdrawal vs standard of care in preventing acute rejection in adult kidney transplant recipients
    Investigator: V. Ram Peddi, MD
    Eligibility: Subjects 18 years and older with end stage renal disease scheduled to undergo a living or deceased donor renal transplant
    Status: Active and open to enrollment
    Contact: Serena Lai, 415-600-1744, Email: LaiS@cpmcri.org about Study BMS 177

    Title: Astagraf XL® to Understand the Impact of Immunosuppression on De Novo DSA Development and Chronic Immune Activation in Kidney Transplantation
    Description: This study will compare the incidence of a two-part composite endpoint consisting of de novo donor specific antibody formation or a designation of "immune activation " on peripheral blood molecular profiling in patients maintained on twice daily, immediate-release tacrolimus versus those maintained on Astagraf XL in the first two years post-transplant.
    Investigator: V. Ram Peddi, MD
    Eligibility: Subjects, 18 to 65 years old, who are recipients of a de novo kidney from a living or deceased donor
    Status: Active and open to enrollment
    Contact: Serena Lai, 415-600-1744, Email: LaiS@cpmcri.org about Study Astellas Astound

    Title: A Phase 3, Randomized, Double-blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of QPI-1002 for Prevention of Delayed Graft Function in Recipients of a Donation After Brain Death Older Donor Kidney Transplant
    Description: A 1 year study evaluating if QPI-1002 can be used to prevent delayed graft function in recipients of an older donor kidneys
    Investigator: V. Ram Peddi, MD
    Eligibility: Subjects, 18 years and older, with dialysis dependent renal failure (at least 2 months prior to transplantation) who are about to receive a kidney transplant from a deceased donor ≥ 45 years of age
    Status: Active and open to enrollment
    Contact: Serena Lai, 415-600-1744, Email: LaiS@cpmcri.org about Study Quark 306

    Title: A Prospective Observational Trial to Evaluate the Correlation of T-SPOT® Response to CMV Infection and T Cell-mediated Acute Graft Rejection
    Description: A non-interventional study evaluating the utility of T-SPOT assays to monitor T cell immune response to CMV and donor antigens
    Investigator: V. Ram Peddi, MD
    Eligibility: : Kidney transplant recipients 18 y/o and older who are CMV seronegative who receive a kidney from a CMV seropositive donor and are within 6 months of their transplant surgery
    Status: Closed to enrollment
    Contact: Alejandra Alvarez, 415-600-1627, Email: AlvasA9@cpmcri.org about Study Oxford Immunotec

    • updated January 2017